title: In vitro and in vivo effects of hesperidin treatment on adult worms of Schistosoma mansoni.
abstract: Hesperidin has been reported to exert a wide range of pharmacological effects, including antifungal, antiviral, antioxidant, anti-inflammatory and anticarcinogenic activities. Herein, the schistosomicidal activity of this compound was evaluated in vitro and in vivo. Using an in vitro assay, a concentration of 200 μg/ml of hesperidin resulted in the mortality of 100% adult worms of Schistosoma (S.) mansoni within 72 h and a partial tegumental alteration in 10% of worms. However, after 144 h incubation, 50 and 100 μg/ml concentrations showed 0% and 10% mortality in adult worms, respectively, without any changes to the tegument. Sublethal doses did not influence egg output nor the development of eggs deposited by pairs of adult worms. In an in vivo study, mice infected with S. mansoni and treated with 600 mg hesperidin/kg body weight showed a respective reduction of 50, 45.2, 50 and 47.5% of males, females, worm pairs and total worm burden. In addition, a respective reduction, based on the number of eggs/g tissue, of 41.5, 63.7 and 58.6% was observed in the liver, intestine and liver/intestinal tissue combined. Furthermore, S. mansoni-specific IgG level significantly increased with hesperidin treatment, whereas IgA and IgE levels were not significantly changed. IgM levels decreased in response to cercarial antigen preparation but were not altered in response to soluble worm or soluble egg antigen. As in hesperidin-treated mice, praziquantel-treated mice showed a similar pattern of specific antibody response to S. mansoni antigens. The present study represents the first report on the effects of the schistosomicidal activity of hesperidin.
authors: Department of Microbiology,College of Medicine, Taif University,Taif,Saudi Arabia.
authors: G
authors: G
authors: Allam
authors: Department of Microbiology,College of Medicine, Taif University,Taif,Saudi Arabia.
authors: A S A
authors: AS
authors: Abuelsaad
mesh_terms: D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000494:pharmacology*; D000909:Antibodies, Helminth / Q000097:blood; D004195:Disease Models, Animal; D005260:Female; D006376:Helminths / Q000187:drug effects*; D006569:Hesperidin / Q000008:administration & dosage* / Q000494:pharmacology*; D007070:Immunoglobulin A / Q000097:blood; D007073:Immunoglobulin E / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D008297:Male; D051379:Mice; D059208:Parasite Load; D012550:Schistosoma mansoni / Q000033:anatomy & histology / Q000187:drug effects* / Q000502:physiology; D012555:Schistosomiasis mansoni / Q000188:drug therapy / Q000469:parasitology; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000871:Anthelmintics; D000909:Antibodies, Helminth; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D007073:Immunoglobulin E; D006569:Hesperidin